Are you living with major depressive disorder (MDD)? Are you experiencing persistent sadness, hopelessness, irritability, restlessness, guilt or worthlessness? Indago is collaborating with Axsome Therapeutics on a research study to assess the safety of solriamfetol in adults with depression (SOL-MDD-301 or PARADIGM).

This study is intended to assess the effectiveness of AXS-05 compared to bupropion in preventing relapse of depressive symptoms in people who have responded to treatment with AXS-05. AXS-05 is not approved for the prevention of relapse and its use in this study is investigational